• In recent weeks, Edwards Lifesciences has drawn attention after exiting its planned JenaValve acquisition, raising 2026 EPS guidance, and emphasizing growth in its Transcatheter Aortic Valve Replacement (TAVR) and mitral platforms amid robust demand for structural heart procedures.
• An interesting angle for investors is how analysts’ upgraded views have clustered around the same theme: TAVR now anchors the company’s long-term focus, with internal platforms prioritized over external deals.
• Next, we’ll examine how this sharper focus on TAVR-driven growth affects Edwards Lifesciences’ investment narrative despite a recent short-term share price decline.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

What Is Edwards Lifesciences' Investment Narrative?

To own Edwards Lifesciences, you really have to buy into one core idea: that TAVR and related structural heart technologies remain central to how clinicians treat valve disease, and that Edwards can keep defending and expanding its position there. The recent decision to walk away from the JenaValve deal and raise 2026 EPS guidance essentially doubles down on that view, signalling confidence in the company’s internal TAVR and mitral platforms rather than bolt‑on acquisitions. In the near term, that shifts the key catalyst firmly toward procedure growth, new product uptake and the upcoming Q4 2025 results, while elevating the risk that any slowdown in TAVR volumes or competitive pressure could matter more than before. The modest share price pullback suggests investors are still weighing how much this sharper focus changes the story.

However, one key risk now sits more squarely in the spotlight for shareholders. Despite retreating, Edwards Lifesciences' shares might still be trading 5% above their fair value. Discover the potential downside here.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$70 to US$97, underscoring how differently private investors view Edwards’ upside. Set that against the renewed emphasis on TAVR growth and the risk of procedure volatility, and it is clear you are weighing very different expectations about how consistently the core franchise can deliver.

Explore 3 other fair value estimates on Edwards Lifesciences - why the stock might be worth 14% less than the current price!

Build Your Own Edwards Lifesciences Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Edwards Lifesciences research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Edwards Lifesciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Edwards Lifesciences' overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.